ÂÜÀòÂÒÂ×

Matthew Scholz is an experienced executive and entrepreneur with a diverse background in biotechnology and technology companies. Matthew is currently the Chief Executive Officer of Oisin Biotechnologies, a company developing therapeutics based on gene activity to kill cells. Matthew is also the Founder and on the Board of Directors of Oisin Biotechnologies. In 2018, they became the Chief Executive Officer of OncoSenX, a position they still hold. In 2020, they co-founded Aegis Life, Inc. and became its Chief Technical Officer. Prior to these roles, Matthew founded Immusoft Corporation in 2009 and served as its CEO until 2018. During their tenure, Immusoft grew into a gene therapy company and received support from prominent investors and research center partners. Matthew was also the Founder and Chief Technology Officer of Immusoft for a period of time. Matthew is also a co-founder and on the Board of Directors of Sigma Genetics, Inc., which they started in 2016. Matthew served as a Board Member for HiveBio Community Lab from 2013 to 2015. In addition, Matthew has a background in technology and was the Chief Executive Officer of Point B Telematics from 2002 to 2008, where they led the development of GPS-based fleet logistics technology.

Matthew Scholz attended the University of Washington from 1998 to 2002 where they earned their Bachelor of Science degree in Computer Science (CSS). Matthew also briefly attended Y Combinator in 2017, although no degree or field of study information was provided for this experience.